#antibody_therapeutics
LightNews LightNews
newsen.bsky.social
Kaigene and Celltrion Forge Alliance to Develop Innovative Antibody Therapies for Autoimmune Disorders#United_States#Rockville#Celltrion#antibody_therapeutics#Kaigene
Kaigene and Celltrion Forge Alliance to Develop Innovative Antibody Therapies for Autoimmune Disorders
Kaigene has signed a licensing deal with Celltrion to develop advanced antibody therapeutics targeting autoimmune diseases, opening new avenues for treatment.
third-news.com
November 4, 2025 at 12:10 AM
newsen.bsky.social
Harbour BioMed and Bristol Myers Squibb Forge Strategic Partnership for Advanced Antibody Development#China#Shanghai#Bristol_Myers_Squibb#Harbour_BioMed#antibody_therapeutics
Harbour BioMed and Bristol Myers Squibb Forge Strategic Partnership for Advanced Antibody Development
Harbour BioMed and Bristol Myers Squibb have entered a global collaboration aimed at developing next-generation multi-specific antibodies, potentially transforming treatments in oncology.
third-news.com
December 17, 2025 at 12:10 AM
newsen.bsky.social
Harbour BioMed Unveils Strong Growth in 2026 Interim Report with Innovative Pipeline Advancements#None#biopharmaceuticals#Harbour_BioMed#antibody_therapeutics
Harbour BioMed Unveils Strong Growth in 2026 Interim Report with Innovative Pipeline Advancements
Harbour BioMed reports impressive results for the first half of 2026, showcasing innovation and growth across its integrated strategy. Explore their advancements.
third-news.com
August 27, 2026 at 2:27 PM
newsen.bsky.social
Antibody Therapeutics Market is Set to Reach $597.1 Billion by 2035#USA#Delray_Beach#pharmaceuticals#Monoclonal_Antibodies#antibody_therapeutics
Antibody Therapeutics Market is Set to Reach $597.1 Billion by 2035
The Antibody Therapeutics Market is projected to grow significantly, reaching $597.1 billion by 2035, driven by advancements in medical innovation and technology.
third-news.com
July 28, 2026 at 2:36 PM
newsen.bsky.social
Harbour BioMed's Strategy Leads to Profitable Results for 2026 and Sustained Growth#None#Biopharmaceutical#Harbour_BioMed#antibody_therapeutics
Harbour BioMed's Strategy Leads to Profitable Results for 2026 and Sustained Growth
Harbour BioMed has reported a profitable forecast for the first half of 2026, marking seven profitable halves in a row and demonstrating strong growth in biopharmaceutical ventures.
third-news.com
July 24, 2026 at 12:13 AM
newsen.bsky.social
Harbour BioMed Appoints Dr. Dhavalkumar Patel as New Scientific Advisor to Boost Innovative Developments#None#Harbour_BioMed#antibody_therapeutics#Dhavalkumar_Patel
Harbour BioMed Appoints Dr. Dhavalkumar Patel as New Scientific Advisor to Boost Innovative Developments
Harbour BioMed has announced the appointment of Dr. Dhavalkumar Patel as its new Scientific Advisor. His extensive experience is set to enhance the company’s immunology pipeline.
third-news.com
June 12, 2026 at 1:30 AM
newsen.bsky.social
Harbour BioMed Unveils 2025 Financial Results and Future Plans for Global Growth#China#Shanghai#biopharmaceuticals#Harbour_BioMed#antibody_therapeutics
Harbour BioMed Unveils 2025 Financial Results and Future Plans for Global Growth
Discover how Harbour BioMed achieved remarkable growth in 2025, supported by strategic collaborations and innovative therapeutics driving its future.
third-news.com
March 30, 2026 at 2:25 PM
newsen.bsky.social
Harbour BioMed Reports Significant Profit Growth Expectations for 2025#United_States#Cambridge#Harbour_BioMed#antibody_therapeutics#Profit_Alert
Harbour BioMed Reports Significant Profit Growth Expectations for 2025
Harbour BioMed announces an impressive profit projection for 2025, showcasing financial growth and strategic collaborations in antibody therapeutics.
third-news.com
February 4, 2026 at 12:04 AM
newsen.bsky.social
Innovative Startups From Hiroshima Set to Enter North American Market in 2025#Japan#Hiroshima#antibody_therapeutics#Hiroshima_Launchpad#Eight_Knot_Inc
Innovative Startups From Hiroshima Set to Enter North American Market in 2025
Six startups from Hiroshima have been selected for the Hiroshima Launchpad: North America 2025 program, aiming to facilitate their entry into the North American market.
third-news.com
August 28, 2025 at 2:55 AM
newsen.bsky.social
LOTTE BIOLOGICS Expands Global Reach with New Contract Manufacturing Deal#South_Korea#Seoul#Ottimo_Pharma#LOTTE_BIOLOGICS#antibody_therapeutics
LOTTE BIOLOGICS Expands Global Reach with New Contract Manufacturing Deal
LOTTE BIOLOGICS has secured a manufacturing deal with Ottimo Pharma to produce antibody therapeutics, marking a significant milestone for the biopharmaceutical company.
third-news.com
June 18, 2025 at 11:19 PM
newsen.bsky.social
QureBio Secures Almost CNY 100 Million for Clinical Advancements in Biopharmaceuticals#China#Shanghai#antibody_therapeutics#Qure_Biotechnology#Efung_Capital
QureBio Secures Almost CNY 100 Million for Clinical Advancements in Biopharmaceuticals
Qure Biotechnology has successfully completed its Series C1 financing, raising nearly CNY 100 million, aiming to enhance clinical trials and develop innovative antibody therapeutics.
third-news.com
June 5, 2025 at 1:40 PM
newsen.bsky.social
Harbour BioMed Welcomes Dr. Ian Y. Liu as Global Head of Legal to Propel Legal Strategies#United_States#Cambridge#Harbour_BioMed#antibody_therapeutics#Dr._Ian_Y._Liu
Harbour BioMed Welcomes Dr. Ian Y. Liu as Global Head of Legal to Propel Legal Strategies
Dr. Ian Y. Liu has been appointed as the Global Head of Legal at Harbour BioMed, bringing extensive expertise in legal and regulatory matters to support the firm's growth.
third-news.com
March 11, 2025 at 12:12 AM
newsen.bsky.social
Harbour BioMed Reports Significant Business Growth and Updates for Stakeholders#China#Shanghai#biotechnology#Harbour_BioMed#antibody_therapeutics
Harbour BioMed Reports Significant Business Growth and Updates for Stakeholders
Harbour BioMed has announced substantial business progress, showcasing profitability and strategic developments in antibody therapeutics for immunology and oncology.
third-news.com
February 14, 2025 at 4:21 AM
hukunamatata.bsky.social
#Antibody_therapeutics approved or in regulatory review in the EU or US

www.antibodysociety.org/resources/ap...
Antibody therapeutics approved or in regulatory review in the EU or US - The Antibody Society
Therapeutic monoclonal antibodies approved or in review in the European Union or the United States
www.antibodysociety.org
January 15, 2025 at 9:22 AM
hukunamatata.bsky.social
#Antibody_therapeutics product data

url: www.antibodysociety.org/antibody-the...
Antibody therapeutics product data - The Antibody Society
The Antibody Society continuously collects data for approved antibody therapeutics and those in regulatory review in any country. A searchable table of this data is below. Products that were granted a...
www.antibodysociety.org
January 15, 2025 at 9:22 AM